Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: A generalization of Steen's study on DRD3 and tardive dyskinesia

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 96, Issue 2, 2000, Pages 187-191

  Eichhammer, Peter ^a   Albus, M ^b   Borrmann Hassenbach, M ^b   Schoeler, A ^a   Putzhammer, A ^a   Frick, U ^a   Klein, H E ^a   Rohrmeier, T ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Universitaetsstrasse 84 ^*

Author keywords

Akathisia; Dopamine D3 receptor variant; Risk factors

Indexed keywords

DOPAMINE 3 RECEPTOR; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ACUTE DISEASE; AKATHISIA, DRUG-INDUCED; AMINO ACID SUBSTITUTION; ANTIPSYCHOTIC AGENTS; DYSKINESIAS; FEMALE; GENE EXPRESSION REGULATION; GERMANY; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; VARIATION (GENETICS);

EID: 0034599828     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(20000403)96:2<187::AID-AJMG13>3.0.CO;2-8     Document Type: Article

References (52)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, et al. 1996. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93:1945-1949.
2. American Psychiatric Association. 1987. Diagnostic and statistical manual of mental disorders, rev. Washington, DC: American Psychiatric Association.
3. Asherson P, Mant R, Holmans P, Williams J, Cardno A, Murphy K, Jones L, Collier D, McGuffin P, Owen MJ. 1996. Linkage, association and mutational analysis of the dopamine D3 receptor gene in schizophrenia. Mol Psychiatry 1:125-132.
4. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
5. Barnes TR, Braude WM. 1984. Persistent akathisia associated with early tardive dyskinesia. Postgrad Med J 60:359-361.
6. Barnes TR, Braude WM. 1985. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42:874-878.
7. Barnes TR, McPhillips MA. 1998. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 13(Suppl 3):S49-57.
8. Binder RL, Levy R. 1981. Extrapyramidal reactions in Asians. Am J Psychiatry 138:1243-1244.
9. Blaisdell GD. 1994. Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry 27:139-146.
10. Braude WM, Barnes TR, Gore SM. 1983. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 143:139-150.
11. Casey DE. 1992. Neuroleptic-induced acute dystonia. In: Lang AE, Weiner WJ, editors. Drug induced movement disorders. Mount Kisco, NY: Futura Publishing. p 21-40.
12. Chengappa KN, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J. 1994. The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 55:142-145.
13. Costall B, Naylor RJ. 1975. The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur J Pharmacol 32:87-92.
14. DeVeaugh-Geiss J. 1982. Prediction and prevention of tardive dyskinesia. In: DeVeaugh-Geiss J, editor. Tardive dyskinesia and related involuntary movement disorders. Bristol, UK: John Wright, p 161-178.
15. Durany N, Thome J, Palomo A, Foley P, Riederer P, Cruz-Sanchez FF. 1996. Homozygosity at the dopamine D3 receptor gene in schizophrenic patients. Neurosci Lett 220:151-154.
16. Eldridge R. 1970. The torsion dystonias: literature review and genetic and clinical studies. Neurology 20:1-78.
17. Fornazzari L, Remington G, Jeffries J. 1991. Akathisia, porphyria and low iron. Can J Psychiatry 36:548.
18. Gaitonde EJ, Morris A, Sivagnanasundaram S, McKenna PJ, Hunt DM, Mollon JD. 1996. Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders. Am J Med Genet 67:455-458.
19. Gerlach J, Lublin H, Peacock L. 1996. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology 14: 35S-39S.
20. Gilbert DB, Cooper SJ. 1995. 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects? Pharmacol Biochem Behav 52:275-280.
21. Jauss M, Schroder J, Pantel J, Bachmann S, Gerdsen I, Mundt C. 1998. Severe akathisia during olanzapine treatment of acute schizophrenia. Pharmacopsychiatry 31:146-148.
22. Jeste DV, Kelsoe JR. 1997. Schizophrenia, tardive dyskinesia, and a D3 receptor gene variant: a new twist on dyskinesias? Mol Psychiatry 2: 86-88.
23. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. 1986. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254-258.
24. Kling-Petersen T, Ljung E, Svensson K. 1995. Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect 102:209-220.
25. Kopala LC, Good KP, Honer WG. 1997. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 17:308-313.
26. Landwehrmeyer B, Mengod G, Palacios JM. 1993. Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res 18:187-192.
27. Lundstrom K, Turpin MP. 1996. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225:1068-1072.
28. Marsden CD, Jenner P. 1980. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10:55-72.
29. Miller CH, Hummer M, Oberbauer H, Kurzthaler I, DeCol C, Fleischhacker WW. 1997. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol 7:51-55.
30. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. 1998. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 59:69-75.
31. Müller N, Voderholzer U, Kurtz G, Straube A. 1994. Tourette's syndrome associated with restless legs syndrome and akathisia in a family. Acta Neurol Scand 89:429-432.
32. Nauta WJ, Smith GP, Faull RL, Domesick VB. 1978. Efferent connections and nigral afferents of the nucleus accumbens septi in the rat. Neuroscience 3:385-401.
33. Pijnenburg AJ, Honig WM, Van der Heyden JA, Van Rossum JM. 1976. Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 35:45-58.
34. Rey MJ, Schulz P, Costa C, Dick P, Tissot R. 1989. Guidelines for the dosage of neuroleptics. Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 4:95-104.
35. Rosebush PI, Mazurek MF. 1999. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 52: 782-785.
36. Sachdev P. 1995. Akathisia and restless legs. New York: Cambridge University Press.
37. Sachdev P, Loneragan C. 1991. Acute drug-induced akathisia is not associated with low serum iron status. Psychopharmacology (Berl) 103: 138-139.
38. Sachdev P, Kruk J. 1994. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 51:963-974.
39. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, Blank K, Koblenzer J, Kahaner K. 1991. Prospective study of tardive dyskinesia incidence in the elderly. J Am Med Assoc 266:2402-2406.
40. Seeman P, Van Tol HH. 1994. Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270.
41. Segman R, Neeman U, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, Dorevitch A, Yakir A, Lerner A, Shelevoy A, et al. 1999. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 4:247-253.
42. Shafer RA, Levant B. 1998. The D3 dopamine receptor in cellular and organismal function. Psychopharmacology (Berl) 135:1-16.
43. Simpson JS. 1996. Familial akathisia and depression treated with nefazodone. Can J Psychiatry 41:539-540.
44. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. 1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
45. Steen VM, Lovlie R, MacEwan T, McCreadie RG. 1997. Dopamine D3-receptor gone variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 2:139-145.
46. Trenkwalder C. 1998. Restless legs syndrome. New York: Springer-Verlag.
47. Umbricht D, Kane JM. 1996. Medical complications of new antipsychotic drugs. Schizophr Bull 22:475-483.
48. van Putten T, May PR, Marder SR. 1984. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41:1036-1039.
49. van Putten T, Marder SR, Mintz J. 1990. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 47:754-758.
50. van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. 1991. Neuroleptic plasma levels. Schizophr Bull 17:197-216.
51. Willner P. 1995. Dopaminergic mechanism in depression and mania. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology. The fourth generation of progress. New York: Raven Press, p 921-931.
52. Wirshing DA, Bartzokis G, Pierre JM, Wirshing WC, Sun A, Tishler TA, Marder SR. 1998. Tardive dyskinesia and serum iron indices. Biol Psychiatry 44:493-498.